Mount Sinai’s CoRE Clinic is recruiting participants for a clinical trial of low-dose Rapamycin for Long COVID. The major focus of this trial is to determine which LC patient subtypes benefit most from the drug. Your participation will help researchers better understand targeted immune modulating therapies for infection-associated chronic illnesses. More information & eligibility details👇🏻

2/ Low-dose Rapamycin is being investigated for its potential to reduce viral activity associated with persistent SARS-CoV-2, EBV or other viruses implicated in Long COVID. The trial is structured to safely and gradually increase the drug’s dose to 4 mg once a week in the treatment group.

3/ Now, with the addition of an open-label phase, participants can opt to receive the drug after the 3 month trial period is completed—even if they were initially randomized to placebo.

4/ Eligibility criteria: -You have been formally diagnosed with Long COVID by a physician -You are 18 years or older -You live in New York and can travel to in-person clinic visits (NOTE: severe patients with restricted travel may be eligible for some at-home visits—reach out to the trial team for more information) Email CoreResearch@MountSinai.org to register.